MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10096-025-05208-3

Медицинская библиотека · European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025

Intravenous combined with nebulized polymyxin B may be effective in treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia: a retrospective cohort study.

Zhang Ye, Chen Jiangtao, Fang Lexin, Wang Min, Zeng Wenqing, Ding Yueping

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To compare the clinical efficacy and safety of intravenous polymyxin B versus the combination of intravenous and nebulized polymyxin B for treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia (CRGNB-HAP), and to explore the risk factors affecting 28-day all-cause mortality.

METHOD: Our retrospective analysis was conducted on data from CRGNB-HAP patients treated in the intensive care unit (ICU) with either intravenous polymyxin B alone or in conjunction with nebulized polymyxin B between November 28, 2018 and May 6, 2024. The primary endpoint was 28-day all-cause mortality, while safety outcomes were also assessed. Logistic regression analysis was utilized to identify the risk factors associated with 28-day all-cause mortality.

RESULT: A total of 82 CRGNB-HAP patients were enrolled, including 38 patients in the intravenous plus nebulized (IV + NL) polymyxin B group and 44 patients in the intravenous (IV) polymyxin B group. The 28-day mortality rate of the IV + NL polymyxin B group was significantly lower than that of the IV polymyxin B group (23.7% vs 61.4%, p < 0.001), and there was no statistically significant difference in the incidence of acute kidney injury between the two groups. Multivariate logistic regression analysis indicated that IV + NL polymyxin B administration was a significant factor in reducing the 28-day mortality rate of CRGNB-HAP patients.

CONCLUSION

Our study found that intravenous combined with nebulized polymyxin B therapy is superior to intravenous monotherapy in the treatment of CRGNB-HAP, resulting in reduced 28-day mortality without increasing renal toxicity.

Для цитирования: Zhang Ye, Chen Jiangtao, Fang Lexin, Wang Min, Zeng Wenqing, Ding Yueping. Intravenous combined with nebulized polymyxin B may be effective in treating carbapenem-resistant gram-negative bacilli hospital-acquired pneumonia: a retrospective cohort study.. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2025. DOI: 10.1007/s10096-025-05208-3.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.